English: Squamous cell- or adenocarcinoma of the oesophagus or oesophago-gastric junction. Dutch: Plaveiselcel- of adenocarcinoom van de slokdarm of gastro-oesophageale overgang.
Conditions
Interventions
Approximately 4-6 weeks after completion of nCRT all included patients will undergo a first clinical response evaluation (CRE-I) including endoscopy with (random) conventional mucosal biopsies of the
Sponsors
Erasmus MC – University Medical Center Rotterdam
Academic Medical Center Amsterdam
University Medical Center Utrecht
Catharina Cancer Center Eindhoven
Atrium Medical Center Heerlen
Eligibility
Inclusion criteria
Inclusion criteria: Patients who are planned to undergo neoadjuvant chemoradiotherapy according to CROSS, followed by surgical resection for histologically proven oesophageal squamous cell carcinoma or adenocarcinoma are eligible for this study. Written, voluntary informed consent
Exclusion criteria
Exclusion criteria: Dementia or altered mental status prohibiting the understanding and giving of informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the correlation between the clinical response during CRE-I and CRE-II (CRE= clinical response evaluation) and the final pathological response in the resection specimen (as measured by the modified tumour regression grading system of Chirieac). | — |
Secondary
| Measure | Time frame |
|---|---|
| R0-resection rates for all included patients that undergo resection. | — |
Contacts
Public ContactB.J. Noordman
Department of Surgery, Room Z-839, Erasmus MC – University Medical Center Rotterdam P.O. Box 2040
Outcome results
None listed